The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Somatic Activation of KIT in Distinct Subtypes of Melanoma
Open accessAbstract
Purpose: Melanomas on mucosal membranes, acral skin (soles, palms, and nail bed), and skin with chronic sun-induced damage have infrequent mutations in BRAF and NRAS, genes within the mitogen-activated protein (MAP) kinase pathway commonly mutated in melanomas on intermittently sun-exposed skin. This raises the question of whether other aberrations are occurring in the MAP kinase cascade in the melanoma types with infrequent mutations of BRAF and NRAS. Patients and Methods: We analyzed array comparative genomic hybridization data from 102 primary melanomas (38 from mucosa, 28 from acral skin, and 18 from skin with and 18 from skin without chronic sun-induced damage) for DNA copy number aberrations specific to melanoma subtypes where mutations in BRAF and NRAS are infrequent. A narrow amplification on 4q12 was found, and candidate genes within it were analyzed. Results: Oncogenic mutations in KIT were found in three of seven tumors with amplifications. Examination of all 102 primary melanomas found mutations and/or copy number increases of KIT in 39% of mucosal, 36% of acral, and 28% of melanomas on chronically sun-damaged skin, but not in any (0%) melanomas on skin without chronic sun damage. Seventy-nine percent of tumors with mutations and 53% of tumors with multiple copies of KIT demonstrated increased KIT protein levels. Conclusion: KIT is an important oncogene in melanoma. Because the majority of the KIT mutations we found in melanoma also occur in imatinib-responsive cancers of other types, imatinib may offer an immediate therapeutic benefit for a significant proportion of the global melanoma burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
Self-citationPDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299
Millauer, B., Wizigmann-Voos, S., Schnürch, H., Martinez, R., Møller, N. P. H., Risau, W., & Ullrich, A. (1993) · Cell · doi:10.1016/0092-8674(93)90573-9 · Cited by 1,927
The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene
Geissler, E. N., Ryan, M. A., & Housman, D. E. (1988) · Cell · doi:10.1016/0092-8674(88)90020-7 · Cited by 1,287
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
Millauer, B., Shawver, L. K., Plate, K. H., Risaui, W., & Ullrich, A. (1994) · Nature · doi:10.1038/367576a0 · Cited by 1,221
The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus
Chabot, B., Stephenson, D. A., Chapman, V. M., Besmer, P., & Bernstein, A. (1988) · Nature · doi:10.1038/335088a0 · Cited by 994
Determinants of BRAF Mutations in Primary Melanomas
Maldonado, J. L., Fridlyand, J., Patel, H., Jain, A. N., Busam, K., Kageshita, T., Ono, T., Albertson, D. G., Pinkel, D., & Bastian, B. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg123 · Cited by 664
Self-citationKIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
Lux, M. L., Rubin, B. P., Biase, T. L., Chen, C.-J., Maclure, T., Demetri, G., Xiao, S., Singer, S., Fletcher, C. D. M., & Fletcher, J. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64946-2 · Cited by 642
Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase
Mol, C. D., Dougan, D. R., Schneider, T. R., Skene, R. J., Kraus, M. L., Scheibe, D. N., Snell, G. P., Zou, H., Sang, B.-C., & Wilson, K. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403319200 · Cited by 635
Bastian, B. C., LeBoit, P. E., Hamm, H., Bröcker, E.-B., & Pinkel, D. (1998) · PubMed · Cited by 513
Self-citationMutations and Copy Number Increase of HRAS in Spitz Nevi with Distinctive Histopathological Features
Bastian, B. C., LeBoit, P. E., & Pinkel, D. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64609-3 · Cited by 455
Self-citationMa, Y., Zeng, S., Metcalfe, D. D., Akin, C., Dimitrijevic, S., Butterfield, J. H., McMahon, G., & Longley, B. J. (2002) · Blood · doi:10.1182/blood.v99.5.1741 · Cited by 449
Effect of c-kit Mutation on Prognosis of Gastrointestinal Stromal Tumors
谷口, 正. (2001) · Cited by 438
Activating c-kit Gene Mutations in Human Germ Cell Tumors
Tian, Q., Frierson, H. F., Krystal, G. W., & Moskaluk, C. A. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65419-3 · Cited by 408
Frost, M. J., Ferrao, P. T., Hughes, T. P., & Ashman, L. K. (2002) · PubMed · Cited by 249
Bastian, B. C., Kashani–Sabet, M., Hamm, H., Godfrey, T. E., Moore, D. H., Bröcker, E.-B., LeBoit, P. E., & Pinkel, D. (2000) · PubMed · Cited by 245
Self-citationWillmore-Payne, C., Holden, J. A., Tripp, S., & Layfield, L. J. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.03.015 · Cited by 230
Isozaki, K., Terris, B., Belghiti, J., Schiffmann, S., Hirota, S., & Vanderwinden, J.-M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64795-5 · Cited by 223
Natali, P. G., Nicotra, M. R., Winkler, A. B., Cavaliere, R., Bigotti, A., & Ullrich, A. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520207 · Cited by 211
Lennartsson, J., Blume-Jensen, P., Hermanson, M., Pontén, E., Carlberg, M., & Rönnstrand, L. (1999) · Oncogene · doi:10.1038/sj.onc.1202929 · Cited by 208
Sihto, H., Sarlomo-Rikala, M., Tynninen, O., Tanner, M., Andersson, L. C., Franssila, K., Nupponen, N. N., & Joensuu, H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.093 · Cited by 196
Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone, K., Belle, P. V., Elenitsas, R., et al. (1997) · PubMed · Cited by 195
Straume, O., & Akslen, L. A. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61688-4 · Cited by 151
Huang, S., Luca, M., Gutman, M., et al. (1996) · PubMed · Cited by 149
Loss of c-kit expression in cultured melanoma cells.
Lassam, N. J., & Bickford, S. (1992) · PubMed · Cited by 147
Tarn, C., Merkel, E., Canutescu, A. A., Shen, W., Skorobogatko, Y. V., Heslin, M. J., Eisenberg, B. L., Birbe, R., Patchefsky, A. S., Dunbrack, R. L., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2515 · Cited by 120
KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells.
Zakut, R., Perlis, R. H., Eliyahu, S., Yarden, Y., Givol, D., Lyman, S. D., & Halaban, R. (1993) · PubMed · Cited by 104
c-KIT receptor expression in cutaneous malignant melanoma and benign melanocytic naevi
Ohashi, A., Funasaka, Y., Ueda, M., & Ichihashi, M. (1996) · Melanoma Research · doi:10.1097/00008390-199602000-00004 · Cited by 84
Shaping of tumor and drug-resistant genomes by instability and selection
Snijders, A. M., Fridlyand, J., Mans, D. A., Segraves, R., Jain, A. N., Pinkel, D., & Albertson, D. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206482 · Cited by 82
Self-citationBeghini, A., Cairoli, R., Morra, E., & Larizza, L. (1998) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.1998.0191 · Cited by 77
(2001) · doi:10.1002/1097-0142(20010801)92:3<657::aid-cncr1367>3.0.co;2-d
Cited by
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Whole-genome landscapes of major melanoma subtypes
Hayward, N. K., Wilmott, J. S., Waddell, N., Johansson, P. A., Field, M. A., Nones, K., Patch, A.-M., Kakavand, H., Alexandrov, L. B., Burke, H., et al. (2017) · Nature · doi:10.1038/nature22071 · Cited by 1,461
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254
KIT as a Therapeutic Target in Metastatic Melanoma
Carvajal, R. D. (2011) · JAMA · doi:10.1001/jama.2011.746 · Cited by 888
Metadata
- Authors
- Curtin, J. A., Busam, K., Pinkel, D., & Bastian, B. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-09-10
- Volume
- 24
- Issue
- 26
- Pages
- 4340-4346
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2156266404
- Cited by
- 1,616
- References
- 32
- FWCI
- 22.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.